ANGIODYNAMICS[®]

AngioDynamics Announces Conference Call for Fiscal Third Quarter 2008 Financial Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--March 19, 2008--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists, and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it plans to report its fiscal third quarter financial results on Wednesday, April 2, 2008, after the close of the financial markets.

Eamonn P. Hobbs, president and chief executive officer, and Joseph Gersuk, executive vice president and CFO, will host an investment community conference call beginning at 4:30 p.m. Eastern time on April 2 to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (800) 240-4186 from the U.S., or for international callers, please dial (303) 262-2139.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' website at http://investor.angiodynamics.com. To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the website. A telephone replay will be available from 7:30 p.m. Eastern time on April 2, 2008 through 11:59 p.m. Eastern time on April 9 by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international) and entering the passcode: 11110709#.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

CONTACT: AngioDynamics, Inc. D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608 jgersuk@AngioDynamics.com or

EVC Group, Inc. Doug Sherk, 415-896-6820 (Investor Relations) dsherk@evcgroup.com Donald Takaya, 415-896-6820 (Investor Relations) dtakaya@evcgroup.com Steve DiMattia, 646-201-5445 (Media)

sdimattia@evcgroup.com

SOURCE: AngioDynamics, Inc.